Results of the multicenter, double-blind clinical trial comparing OMS103HP to vehicle control in 344 patients revealed worse than expected results. The Symptoms Subscale of the Knee Injury and Osteoarthritis Outcome Score did not reach clinical significance, however the product did record statistically significant postoperative pain reduction.
OMS103HP is comprised of only anti-inflammatory active ingredients and delivered directly into the joint in the arthroscopic irrigation system. It is designed to avoid reported damage to cartilage cells due to intra-articular delivery of local anesthetics as well as other detrimental effects of systematically delivered analgesics.
Since the announcement, company shares have dropped 9 percent, according to a Galaxy Stocks report. However, the company announced it would continue to pursue a second late-stage trial of the product during the first half of next year.
http://galaxystocks.com/27000/nasdaq-news/omeros-nasdaqomer-plunges-on-fail-of-knee-surgery-drug-study-omer-arna-aezs-gild-dndn/
More Articles on Orthopedic Surgery:
Orthopaedic and Spine Institute Opens Pediatric Orthopedic Center
Regional Orthopedics Opens New Facility in New York
Orthopaedic Institute of Western Kentucky Signs 10-Year Contract With Local Schools
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.